MGC Pharmaceuticals - PDMR Notification
28/03/2024 09:12
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240328:nRSb6895Ia&default-theme=true
RNS Number : 6895I MGC Pharmaceuticals Limited 28 March 2024
MGC Pharmaceuticals Ltd.
PDMR Notification
28 March 2024
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that
the following Persons Discharging Managerial Responsibilities (PDMR) were
issued a combined 240,000 unlisted options as approved at a meeting of
shareholders on 18 March 2024. This notification is made in accordance the UK
Market Abuse Regulations.
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Daniel Robinson
2 Reason for the notification
(a) Position Non-Executive Director
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Unlisted options exercisable at A$0.42 on or before 28 March 2027.
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Grant of Options over Ordinary Shares
(d) Currency Price Volume Total
AUD 0.00 120,000 N/A
Aggregated information
AUD 0.00 120,000 N/A
(e) Date of transaction 28 March 2024
(f) Place of transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Layton Mills
2 Reason for the notification
(a) Position Non-Executive Director
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Unlisted options exercisable at A$0.42 on or before 28 March 2027.
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Grant of Options over Ordinary Shares
(d) Currency Price Volume Total
AUD 0.00 120,000 N/A
Aggregated information
AUD 0.00 120,000 N/A
(e) Date of transaction 28 March 2024
(f) Place of transaction Outside a trading venue
-Ends-
Authorised for release by the Company Secretary, for further information
please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Rowan Harland
CEO & Managing Director Company Secretary
+61 8 6555 2950 +61 8 6555 2950
info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk) info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)
UK IR/PR Advisers UK Brokers
IFC Advisory Oberon Capital
Graham Herring / Tim Metcalfe / Zach Cohen Aimee McCusker / Adam Pollock
+44 203 934 6630 +44 203 179 5300
mgcpharma@investor-focus.co.uk (mailto:mgcpharma@investor-focus.co.uk) aimeemccusker@oberoninvestments.com
(mailto:aimeemccusker@oberoninvestments.com) adampollock@oberoninvestments.com
(mailto:adampollock@oberoninvestments.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGCGDXLGDDGSI
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group